CAMBRIDGE, Mass., May 27, 2020 /PRNewswire/ -- Synlogic
(Nasdaq: SYBX) today will host its first Virtual R&D Event
which will include presentations from members of the Synlogic
executive team providing an in-depth review of Synlogic's Synthetic
Biotic platform and programs for the treatment of metabolic
diseases, inflammatory and immune disorders, and cancer. In
addition, guest speaker David S.
Goldfarb, M.D., Professor of Medicine and Physiology, NYU
School of Medicine, Clinical Chief, Nephrology Division, NYU
Langone Health, Chief, Nephrology Section, New York VA Medical
Center, will present an overview of enteric hyperoxaluria and a
patient perspective.
Registration information for the event can be accessed under
"Event Calendar" in the Investors & Media section of the
Synlogic website. The R&D Event presentations are scheduled to
begin at 12:30 pm ET today,
May 27, 2020. A live audio webcast of
the presentation and a slide deck will be available via the
company's Investor Relations website. Following the live webcast,
an archived version will be available on the website for 90
days.
About Synlogic
Synlogic is pioneering the development of a novel class of
living medicines, Synthetic BioticTM medicines, based on
its proprietary drug development platform. Synlogic leverages the
tools and principles of synthetic biology to genetically engineer
beneficial microbes to perform or deliver critical functions
missing or damaged due to disease. When delivered orally, Synthetic
Biotic medicines are designed to function in the gut to compensate
for the dysfunctional metabolic pathway and have a systemic effect,
with the potential to significantly improve symptoms of disease for
affected patients. The Company's lead program in this area,
SYNB1618, targets PKU. In addition, the Company is leveraging the
broad potential of its platform to create Synthetic Biotic
medicines for the treatment of more common diseases, including
inflammatory and immune disorders, and cancer. Synlogic's first
immuno-oncology program, SYNB1891, is in clinical development for
the treatment of solid tumors and lymphoma. For more
information, please visit www.synlogictx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synlogic-hosts-first-virtual-rd-event-301065676.html
SOURCE Synlogic, Inc.